Associated Papers
Analysis of matched primary and recurrent BRCA1/2 mutation-associated tumors identifies recurrence-specific drivers.
Shah JB et al.
Nature Communications, 2022
36344544 (PubMed )
Supplement: 41467_2022_34523_MOESM3_ESM.xlsx › PrimaryRecurrent_cohort_tumors
Human BRCA pathogenic variants were originated during recent human history.
Li J et al.
Life Science Alliance, 2022
35165121 (PubMed )
Supplement: LSA-2021-01263_TableS2.xlsx › BRCA1
BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance.
Wang Y et al.
Nature Communications, 2019
Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells.
Dev H et al.
Nature Cell Biology, 2018
30022119 (PubMed )
Supplement: NIHMS78112-supplement-Supplementary_table_5.xlsx › Fig_7b
Heterogeneous prevalence of recurrent BRCA1 and BRCA2 mutations in Spain according to the geographical area: implications for genetic testing.
Diez O et al.
Familial Cancer, 2010
Twenty-three novel BRCA1 and BRCA2 sequence alterations in breast and/or ovarian cancer families of Eastern Spain.
Esteban Cardeñosa E et al.
Breast Cancer Research and Treatment, 2008
Select a paper to view details